Pharma Leader Series: Top Pre-Filled Injection Device Manufacturers 2013-2023
Report Details
Pre-filled syringes and related devices - discover companies' revenue prospects
How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices.
Our updated study lets you assess leading companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2023. There you see financial results, interviews, trends, opportunities and revenue predictions.
That way, you discover information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.
See forecasts and discussions to help you stay ahead in knowledge
In our study you find analytical profiles of 15 top companies - and analyses of the overall industry - with historical data, revenue forecasts and growth rates. You also see qualitative analysis, business outlooks and developments. You gain 80 tables and 32 charts.
Our work lets you assess the most lucrative areas of those drug delivery technologies, seeing opportunities both for makers of drugs and of those medical injection devices.
That way you can stay ahead in knowledge of the industry and market for these medical devices:
What you discover in our company profiles
Our report profiles 15 leading companies across four sectors of the pre-filled injection devices market. The content of each profile differs, depending on the company. In general, however, a profile contains the following information:
Those interviews include views on the development of the pre-filled syringe market. Our study also shows comparison and analysis of those interviews, summarising their lessons.
See prospects for leading pre-filled syringe manufacturers
Our study gives you discussions and financial analyses for leading producers of pre-filled syringes:
Suppliers and users of pre-filled injection systems will benefit from 2013 onwards. Next, our investigation analyses developers and producers of associated technologies.
What's the outlook for manufacturers of pre-filled syringe components?
Our report shows you developments and revenue prospects for leading producers of syringe components:
Our work shows you where sales growth can occur. Many opportunities remain, with expanding revenues possible from 2013 to 2023.
Find prospects for leading pen injector and autoinjector producers
In our study you also see commercial outlooks for top manufacturers of pen injectors and autoinjectors:
Who are the leading pre-filled syringe contract manufacturers?
Our work assesses contract manufacturing organisations (CMOs) in that field. There you discover activities of these prominent organisations:
Where is that overall area of drug delivery heading?
Our analysis predicts overall world revenues for those pre-filled injection devices - the drug delivery technology - will reach $4.47bn in 2017. These will expand further to 2023.
Greater use of biologics and vaccines will raise demand for parenteral delivery systems. Many opportunities exist, especially for plastic syringes and ready-to-use containment of labile drugs and other complex pharmaceuticals. Our study explains.
What about applications? The incidence of diabetes and expansion of the home healthcare market, in particular, will stimulate demand for pre-filled drug injection systems.
What about market needs? Medical injection systems giving improved clinical efficacy, safety and convenience will achieve commercial success this decade, our analyses show. See, then, prospects from 2013 to 2023 for that market and its leading companies.
Seven ways Pharma Leader Series: Top Pre-Filled Injection Device Manufacturers 2013-2023 helps you
To sum up then, our investigation gives you the following knowledge:
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Discover prospects for leading drug injection device companies by ordering now
Our investigation is for everyone needing analysis of the industry and market for drug delivery via injections. There you find data, trends, opportunities and predictions. Please order our report now.
Pre-filled syringes and related devices - discover companies' revenue prospects
How are companies in the pre-filled syringe industry performing? Visiongain's report gives you data, analyses and discussions for producers of those drug delivery devices.
Our updated study lets you assess leading companies in the pre-filled (ready-to-fill) syringe industry and market, showing you their prospects to 2023. There you see financial results, interviews, trends, opportunities and revenue predictions.
That way, you discover information you need on established and emerging companies. Read on to scan those organisations and see what their future market could be worth.
See forecasts and discussions to help you stay ahead in knowledge
In our study you find analytical profiles of 15 top companies - and analyses of the overall industry - with historical data, revenue forecasts and growth rates. You also see qualitative analysis, business outlooks and developments. You gain 80 tables and 32 charts.
Our work lets you assess the most lucrative areas of those drug delivery technologies, seeing opportunities both for makers of drugs and of those medical injection devices.
That way you can stay ahead in knowledge of the industry and market for these medical devices:
- Plastic syringes
- Glass syringes
- Related injection products and disposable (single-use) systems for injecting drugs.
What you discover in our company profiles
Our report profiles 15 leading companies across four sectors of the pre-filled injection devices market. The content of each profile differs, depending on the company. In general, however, a profile contains the following information:
- Overview of the company, including its history in the pre-filled injection device market
- Discussions of the company's pre-filled injection device product/service portfolio, including an identification of main clients
- Analysis of the company's recent financial performance, for overall revenue and, where possible, pre-filled injection device revenue
- Assessment of its recent developments in the pre-filled injection device market, e.g. acquisitions, facility expansions, product launches and collaborations with the pharmaceutical industry
- Qualitative analysis of the company, identifying strengths over its competitors, as well as its opportunities for sales growth
- Prediction of revenue for the period 2013-2023 (for 10 of the 15 companies).
Those interviews include views on the development of the pre-filled syringe market. Our study also shows comparison and analysis of those interviews, summarising their lessons.
See prospects for leading pre-filled syringe manufacturers
Our study gives you discussions and financial analyses for leading producers of pre-filled syringes:
- Becton, Dickinson & Co. (BD)
- Gerresheimer
- Schott
- Nipro
- Nuova Ompi.
Suppliers and users of pre-filled injection systems will benefit from 2013 onwards. Next, our investigation analyses developers and producers of associated technologies.
What's the outlook for manufacturers of pre-filled syringe components?
Our report shows you developments and revenue prospects for leading producers of syringe components:
- Aptar Stelmi
- Datwyler Holding
- West Pharmaceutical Services.
Our work shows you where sales growth can occur. Many opportunities remain, with expanding revenues possible from 2013 to 2023.
Find prospects for leading pen injector and autoinjector producers
In our study you also see commercial outlooks for top manufacturers of pen injectors and autoinjectors:
- Haselmeier
- Owen Mumford
- SHL Group
- Ypsomed.
Who are the leading pre-filled syringe contract manufacturers?
Our work assesses contract manufacturing organisations (CMOs) in that field. There you discover activities of these prominent organisations:
- Catalent
- Hospira One2One
- Vetter Pharma.
Where is that overall area of drug delivery heading?
Our analysis predicts overall world revenues for those pre-filled injection devices - the drug delivery technology - will reach $4.47bn in 2017. These will expand further to 2023.
Greater use of biologics and vaccines will raise demand for parenteral delivery systems. Many opportunities exist, especially for plastic syringes and ready-to-use containment of labile drugs and other complex pharmaceuticals. Our study explains.
What about applications? The incidence of diabetes and expansion of the home healthcare market, in particular, will stimulate demand for pre-filled drug injection systems.
What about market needs? Medical injection systems giving improved clinical efficacy, safety and convenience will achieve commercial success this decade, our analyses show. See, then, prospects from 2013 to 2023 for that market and its leading companies.
Seven ways Pharma Leader Series: Top Pre-Filled Injection Device Manufacturers 2013-2023 helps you
To sum up then, our investigation gives you the following knowledge:
- Revenues to 2023 for the overall world market and two product categories - you discover that industry's prospects, finding lucrative areas for investments and revenues
- Profiles of 15 leading companies - you assess products, services, sales results and outlooks, also gaining 10 revenue forecasts to 2023
- Interviews with 5 top companies in the industry - you discover debates and opinions to help you stay ahead
- Competition and opportunities - you see what affects that industry and shapes its future, especially needs for injecting biologics, biosimilars and other viscous drugs
- Discussions of technological progress and market expansion - you investigate developments, exploring possibilities for technological and commercial advances
- Analysis of what stimulates and restrains that industry and market - you assess challenges and strengths, helping you compete and gain advantages
- Prospects for established competitors and firms seeking to enter the sector - you explore needs, practices and outlooks for future success.
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.
With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.
Discover prospects for leading drug injection device companies by ordering now
Our investigation is for everyone needing analysis of the industry and market for drug delivery via injections. There you find data, trends, opportunities and predictions. Please order our report now.
1. EXECUTIVE SUMMARY
1.1 Outlook for the Leading Pre-Filled Injection Device Manufacturers 2013-2023
1.2 Reports Contents
1.2.1 Company Profile Contents
1.3 Research Analysis and Methods
1.3.1 Terminology Used in the Report
2. INTRODUCTION TO THE PRE-FILLED INJECTION DEVICE MARKET
2.1 A Brief History of Syringes and Pre-Filled Injection Systems
2.2 Components of Pre-Filled Syringes
2.2.1 Glass vs. Plastic Syringes
2.2.2 Pen Injectors and Autoinjectors
2.2.3 Benefits and Weaknesses of Pre-Filled Injection Devices
2.3 The Pre-Filled Injection Device Market 2013-2023
2.3.1 A Rapidly Growing Market 2011-2012
2.3.2 Contract Manufacturing as a Sector of the Pre-Filled Syringe Market
2.3.3 Demand is Greatest in Developed Countries
2.3.4 Pre-Filled Syringe Market Forecast 2013-2023
2.4 Key Trends in the Pre-Filled Injection Device Market 2013-2023
2.4.1 Increased Market Consolidation
2.4.2 Increased Development of Biologics and Biosimilars
2.4.3 The Rise in At-Home Care
2.4.4 Greater Demands for Safety Leading Innovation
2.4.5 The Threat from Other Drug Delivery Technologies
3. LEADING PRE-FILLED SYRINGE MANUFACTURERS 2013-2023
3.1 Becton, Dickinson & Co. (BD)
3.1.1 BD Has a Broad Pre-Filled Syringe Product Range
3.1.1.1 BD Hypak: The World's First Glass Pre-Filled Syringe
3.1.1.2 BD Sterifill
3.1.1.3 BD Soluvia
3.1.1.4 Uniject is a Product for Emerging Markets
3.1.1.5 BD Physioject: BD's Autoinjector
3.1.1.6 BD Markets Pen Injectors for Lyophilised Drugs
3.1.1.7 BD's Proprietary Syringe Safety Systems
3.1.2 Steady Growth for BD's Pre-Filled Injection Device Revenue 2011-2012
3.1.3 BD Acquires Safety Syringes
3.1.4 Many New Product Launches Planned
3.1.4.1 BD Vystra Disposable Pen is the Company's Latest Pre-Filled Injection System
3.1.5 What Opportunities Are There for BD in this Market?
3.1.5.1 BD Will Continue to Expand
3.1.6 BD Pharmaceutical Systems: Revenue Forecast 2013-2023
3.2 Gerresheimer
3.2.1 Gerresheimer's Pre-Filled Syringe Products
3.2.1.1 Ready-To-Fill (RTF) Syringes
3.2.1.2 Gerresheimer Licensed Polymer Syringes from Taisei Kako
3.2.1.3 Gerresheimer Began Manufacturing Pen Injectors in 2009
3.2.2 Strong Revenue Growth for Gerresheimer 2010-2012
3.2.3 Rapid Growth in the Plastic Systems Division
3.2.3.1 Gerresheimer Expands in India
3.2.4 RTF Expansion Has Been More Steady
3.2.5 Gerresheimer: SWOT Analysis 2013-2023
3.2.5.1 Rapid Growth Planned for Emerging Markets
3.2.5.2 Gerresheimer is Well Placed for Biologics Growth
3.2.6 Growing Market Share for Gerresheimer's Pen Injectors?
3.3 Schott
3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
3.3.1.1 Forma 3s Glass Syringes
3.3.1.2 TopPac Polymer Syringes
3.3.1.3 InJentle Syringes for Sensitive Drug Products
3.3.2 Schott: Financial Performance 2008-2011
3.3.3 Expansion in Developed and Emerging Markets
3.3.3.1 Growth in India, Russia and China
3.3.4 Schott Is Well-Placed for Growing Biologics Demand
3.3.4.1 Becoming a Leader in Russia
3.3.5 Schott: Expert Opinion on the Pre-Filled Injection Device Market
3.4 Nipro: A Market Leader Through its MGlas Acquisition
3.4.1 Pre-Filled Syringe Product Overview
3.4.2 Nipro is Expanding Globally
3.4.3 Nipro: SWOT Analysis 2013-2023
3.4.3.1 Responding to Rising Diabetes Incidence
3.5 Nuova Ompi: A Glass Manufacturing Specialist
3.5.1 Nuova Markets Glass Pre-Filled Syringes and Cartridges
3.5.1.1 EZ-Fill Syringes
3.5.1.2 Extra High Quality (XQ) Syringes
3.5.2 Focused on Growth for Cartridges and Vials Manufacturing in Emerging Markets
3.5.3 Nuova Ompi Offers Customised Manufacturing Solutions
3.5.3.1 Nuova's Products for the Biologics Market
3.5.3.2 Significant Investment Planned to 2016
3.5.4 Nuova Ompi: Company Insight
3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2013-2023
3.6.1 The Need for Advanced Safety Systems
3.6.2 Meeting the Demands of Biologic and Biosimilar Developers
3.6.3 Product Portfolio Diversity
3.6.4 What Demand is there in Emerging Markets?
3.7 High Barriers to Market Entry Will Limit Competition to 2023
3.7.1 Unilife Manufactures Novel Pre-Filled Injection Systems
3.7.2 Revolutions Medical: A Disposable Syringe Manufacturer Entering the Pre-Filled Market
4. LEADING PRE-FILLED SYRINGE COMPONENT MANUFACTURERS 2013-2023
4.1 Aptar Stelmi is a Pharma Packaging Specialist
4.1.1 Aptar Stelmi's Pre-Filled Syringe Components
4.1.1.1 Stelmi's Rigid Needle Shields
4.1.2 Aptar Has Access to the Autoinjector Market Through Oval Medical
4.1.3 Aptar Stelmi's Revenue Grows Over 10% Annually 2004-2012
4.1.4 Aptar Stelmi: SWOT Analysis 2013-2023
4.1.4.1 Regional Expansion is Important for Continued Growth
4.1.5 Continued Revenue Growth for Aptar Stelmi 2013-2023
4.2 Datwyler Holding
4.2.1 Datwyler's Pre-Filled Syringe Components
4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2007-2012
4.2.3 Datwyler Is Focused on High-Value Expansion
4.2.4 Growth in Emerging Markets
4.2.5 Datwyler: SWOT Analysis
4.2.6 What Will Drive Growth for Datwyler Pharma Packaging to 2023?
4.2.7 Datwyler: Pre-Filled Injection Device Market Insight
4.3 West Pharmaceutical Services
4.3.1 West Manufactures Syringes and Syringe Components
4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
4.3.1.2 MixJect for Lyophilised Drugs
4.3.1.3 West's Self-Injection Systems
4.3.1.4 West Markets Three Safety Systems
4.3.2 Recent Financial Performance
4.3.3 Collaborations with Big Pharma for Product Development
4.3.4 West Enters the Indian Market
4.3.5 West: Opportunities for Growth 2013-2023
4.3.6 Pre-Filled Injection Device Revenue Forecast 2013-2023
4.3.7 West Pharmaceutical Services: Company Insight
4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2013-2023
4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
4.4.1.1 Tip-top Offers Three Safety Products for Pre-Filled Syringes
4.4.1.2 Rexam Receives Approval for its Safe'n'Sound Passive Safety System
4.4.2 Entering the Autoinjector Market
4.4.3 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets
5. LEADING PEN INJECTOR AND AUTOINJECTOR MANUFACTURERS 2013-2023
5.1 Haselmeier
5.1.1 Haselmeier Markets Five Injection Systems
5.1.1.1 Axis Pen Systems
5.1.1.2 i-Pen: Haselmeier's Insulin Pen Injector
5.1.2 Company Growth in Germany and India
5.1.3 Haselmeier: Opportunities for Expansion 2013-2023
5.2 Owen Mumford
5.2.1 Autoinjector and Pen Injector Overview
5.2.1.1 Autoject
5.2.1.2 Autopen
5.2.1.3 SimpleJect: Designed for RA Patients
5.2.2 Recent Financial Performance
5.2.3 Innovative Products to Drive Growth
5.2.4 Expanding in Established and New Markets
5.2.5 Owen Mumford: SWOT Analysis 2013-2023
5.2.6 Owen Mumford: Company Revenue Forecast 2013-2023
5.3 SHL Group
5.3.1 SHL Manufactures a Broad Range of Injection Devices
5.3.1.1 Molly Autoinjector
5.3.1.2 DAI Autoinjectors
5.3.2 SHL Group Continues to Grow in Taiwan
5.3.3 SHL Group: Pen Injector and Autoinjector Market Outlook 2013-2023
5.4 Ypsomed
5.4.1 Product Portfolio
5.4.1.1 YpsoPen
5.4.1.2 ServoPen
5.4.1.3 UnoPen
5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
5.4.1.5 Ypsomed Markets Two Autoinjectors
5.4.2 Ypsomed: Financial Performance 2009-2012
5.4.2.1 Continued Delivery Devices Revenue Decline for FY 2013
5.4.3 A Focus on Diabetes
5.4.4 What Are Ypsomed's Strengths in the Pre-Fill Injection Device Market 2013?
5.4.5 Ypsomed Delivery Devices Revenue Forecast 2013-2023
5.4.6 Ypsomed: Company Insight
5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2013-2023
5.5.1 A Highly Competitive Market 2013-2023
5.5.2 How Are Companies Differentiating Their Autoinjectors?
5.5.3 Rising Demand in At-Home Care
5.5.3.1 Specific Demands in RA and MS
5.5.4 Contract Manufacturing for Autoinjectors
6. LEADING PRE-FILLED SYRINGE CONTRACT MANUFACTURERS 2013-2023
6.1 Catalent is the World's Largest CMO
6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
6.1.2 Catalent Offers an Autoinjector
6.1.3 Catalent Pharma Solutions: Financial Performance 2011-2012
6.1.4 Expanding Filling Capacity for Clinical Trial Materials
6.1.5 Catalent: SWOT Analysis 2013-2023
6.1.6 Catalent Pre-Filled Syringe and Cartridge Filling Revenue Forecast 2013-2023
6.2 Hospira One2One
6.2.1 Hospira and the Pre-Filled Injection Device Industry
6.2.1.1 iSecure Syringe: Hospira's Pre-Filled Injection System
6.2.2 Facility Expansion in Emerging Markets
6.2.3 Hospira: Market Outlook 2013-2023
6.2.4 Hospira One2One: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.3 Vetter Pharma
6.3.1 Vetter Is an Injectable Manufacturing Specialist
6.3.2 Vetter Grows in the US and Germany
6.3.3 New Services and Collaborations
6.3.4 Vetter: SWOT Analysis 2013-2023
6.3.5 Outlook for Vetter: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.4 The Competitive Outlook for Leading CMOs in the Market 2013-2023
6.4.1 Biologics, Lyophilisation and Dual-Chamber Syringes
6.4.2 An Increasingly Competitive Market?
6.5 Other Pre-Filled Syringe Contract Manufacturers 2013
6.5.1 ROVI Has the Capacity to be a Market Leader
6.5.1.1 ROVI CM's Pre-Filled Syringe Capabilities
6.5.2 AMRI Entered the Market Through its Acquisition of HCM
6.5.2.1 AMRI's Recent Financial Performance
6.5.3 Boehringer Ingelheim
7. CONCLUSIONS FROM OUR STUDY
7.1 Outlook for the Pre-Filled Injection System Market 2013-2023
7.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2013-2023
7.2.1 How Will the Leading Companies' Revenues Grow to 2023?
7.3 Company Insight Analysis: Common and Different Growth Strategies 2013-2023
7.3.1 How Have Customer Demands Changed in Recent Years?
7.3.1.1 How Will These Demands Change in the Future?
7.3.2 How Important Will Emerging Markets Be in this Decade?
7.4 Concluding Remarks
1.1 Outlook for the Leading Pre-Filled Injection Device Manufacturers 2013-2023
1.2 Reports Contents
1.2.1 Company Profile Contents
1.3 Research Analysis and Methods
1.3.1 Terminology Used in the Report
2. INTRODUCTION TO THE PRE-FILLED INJECTION DEVICE MARKET
2.1 A Brief History of Syringes and Pre-Filled Injection Systems
2.2 Components of Pre-Filled Syringes
2.2.1 Glass vs. Plastic Syringes
2.2.2 Pen Injectors and Autoinjectors
2.2.3 Benefits and Weaknesses of Pre-Filled Injection Devices
2.3 The Pre-Filled Injection Device Market 2013-2023
2.3.1 A Rapidly Growing Market 2011-2012
2.3.2 Contract Manufacturing as a Sector of the Pre-Filled Syringe Market
2.3.3 Demand is Greatest in Developed Countries
2.3.4 Pre-Filled Syringe Market Forecast 2013-2023
2.4 Key Trends in the Pre-Filled Injection Device Market 2013-2023
2.4.1 Increased Market Consolidation
2.4.2 Increased Development of Biologics and Biosimilars
2.4.3 The Rise in At-Home Care
2.4.4 Greater Demands for Safety Leading Innovation
2.4.5 The Threat from Other Drug Delivery Technologies
3. LEADING PRE-FILLED SYRINGE MANUFACTURERS 2013-2023
3.1 Becton, Dickinson & Co. (BD)
3.1.1 BD Has a Broad Pre-Filled Syringe Product Range
3.1.1.1 BD Hypak: The World's First Glass Pre-Filled Syringe
3.1.1.2 BD Sterifill
3.1.1.3 BD Soluvia
3.1.1.4 Uniject is a Product for Emerging Markets
3.1.1.5 BD Physioject: BD's Autoinjector
3.1.1.6 BD Markets Pen Injectors for Lyophilised Drugs
3.1.1.7 BD's Proprietary Syringe Safety Systems
3.1.2 Steady Growth for BD's Pre-Filled Injection Device Revenue 2011-2012
3.1.3 BD Acquires Safety Syringes
3.1.4 Many New Product Launches Planned
3.1.4.1 BD Vystra Disposable Pen is the Company's Latest Pre-Filled Injection System
3.1.5 What Opportunities Are There for BD in this Market?
3.1.5.1 BD Will Continue to Expand
3.1.6 BD Pharmaceutical Systems: Revenue Forecast 2013-2023
3.2 Gerresheimer
3.2.1 Gerresheimer's Pre-Filled Syringe Products
3.2.1.1 Ready-To-Fill (RTF) Syringes
3.2.1.2 Gerresheimer Licensed Polymer Syringes from Taisei Kako
3.2.1.3 Gerresheimer Began Manufacturing Pen Injectors in 2009
3.2.2 Strong Revenue Growth for Gerresheimer 2010-2012
3.2.3 Rapid Growth in the Plastic Systems Division
3.2.3.1 Gerresheimer Expands in India
3.2.4 RTF Expansion Has Been More Steady
3.2.5 Gerresheimer: SWOT Analysis 2013-2023
3.2.5.1 Rapid Growth Planned for Emerging Markets
3.2.5.2 Gerresheimer is Well Placed for Biologics Growth
3.2.6 Growing Market Share for Gerresheimer's Pen Injectors?
3.3 Schott
3.3.1 Schott Markets Glass and Plastic Pre-Filled Syringes
3.3.1.1 Forma 3s Glass Syringes
3.3.1.2 TopPac Polymer Syringes
3.3.1.3 InJentle Syringes for Sensitive Drug Products
3.3.2 Schott: Financial Performance 2008-2011
3.3.3 Expansion in Developed and Emerging Markets
3.3.3.1 Growth in India, Russia and China
3.3.4 Schott Is Well-Placed for Growing Biologics Demand
3.3.4.1 Becoming a Leader in Russia
3.3.5 Schott: Expert Opinion on the Pre-Filled Injection Device Market
3.4 Nipro: A Market Leader Through its MGlas Acquisition
3.4.1 Pre-Filled Syringe Product Overview
3.4.2 Nipro is Expanding Globally
3.4.3 Nipro: SWOT Analysis 2013-2023
3.4.3.1 Responding to Rising Diabetes Incidence
3.5 Nuova Ompi: A Glass Manufacturing Specialist
3.5.1 Nuova Markets Glass Pre-Filled Syringes and Cartridges
3.5.1.1 EZ-Fill Syringes
3.5.1.2 Extra High Quality (XQ) Syringes
3.5.2 Focused on Growth for Cartridges and Vials Manufacturing in Emerging Markets
3.5.3 Nuova Ompi Offers Customised Manufacturing Solutions
3.5.3.1 Nuova's Products for the Biologics Market
3.5.3.2 Significant Investment Planned to 2016
3.5.4 Nuova Ompi: Company Insight
3.6 Pre-Filled Syringe Manufacturers: Competitor Analysis 2013-2023
3.6.1 The Need for Advanced Safety Systems
3.6.2 Meeting the Demands of Biologic and Biosimilar Developers
3.6.3 Product Portfolio Diversity
3.6.4 What Demand is there in Emerging Markets?
3.7 High Barriers to Market Entry Will Limit Competition to 2023
3.7.1 Unilife Manufactures Novel Pre-Filled Injection Systems
3.7.2 Revolutions Medical: A Disposable Syringe Manufacturer Entering the Pre-Filled Market
4. LEADING PRE-FILLED SYRINGE COMPONENT MANUFACTURERS 2013-2023
4.1 Aptar Stelmi is a Pharma Packaging Specialist
4.1.1 Aptar Stelmi's Pre-Filled Syringe Components
4.1.1.1 Stelmi's Rigid Needle Shields
4.1.2 Aptar Has Access to the Autoinjector Market Through Oval Medical
4.1.3 Aptar Stelmi's Revenue Grows Over 10% Annually 2004-2012
4.1.4 Aptar Stelmi: SWOT Analysis 2013-2023
4.1.4.1 Regional Expansion is Important for Continued Growth
4.1.5 Continued Revenue Growth for Aptar Stelmi 2013-2023
4.2 Datwyler Holding
4.2.1 Datwyler's Pre-Filled Syringe Components
4.2.1.1 Omniflex Coating: An Alternative to Silicone Oil
4.2.2 Demand from Insulin Manufacturers Drives Revenue Growth 2007-2012
4.2.3 Datwyler Is Focused on High-Value Expansion
4.2.4 Growth in Emerging Markets
4.2.5 Datwyler: SWOT Analysis
4.2.6 What Will Drive Growth for Datwyler Pharma Packaging to 2023?
4.2.7 Datwyler: Pre-Filled Injection Device Market Insight
4.3 West Pharmaceutical Services
4.3.1 West Manufactures Syringes and Syringe Components
4.3.1.1 Daikyo Crystal Zenith: Licensed from Daikyo Seiko
4.3.1.2 MixJect for Lyophilised Drugs
4.3.1.3 West's Self-Injection Systems
4.3.1.4 West Markets Three Safety Systems
4.3.2 Recent Financial Performance
4.3.3 Collaborations with Big Pharma for Product Development
4.3.4 West Enters the Indian Market
4.3.5 West: Opportunities for Growth 2013-2023
4.3.6 Pre-Filled Injection Device Revenue Forecast 2013-2023
4.3.7 West Pharmaceutical Services: Company Insight
4.4 Pre-Filled Syringe Component Manufacturers: Competitor Analysis 2013-2023
4.4.1 How Can Component Manufacturers React to Increased Safety Demands?
4.4.1.1 Tip-top Offers Three Safety Products for Pre-Filled Syringes
4.4.1.2 Rexam Receives Approval for its Safe'n'Sound Passive Safety System
4.4.2 Entering the Autoinjector Market
4.4.3 Component Manufacturers Following Pre-Filled Syringe Manufacturers to Emerging Markets
5. LEADING PEN INJECTOR AND AUTOINJECTOR MANUFACTURERS 2013-2023
5.1 Haselmeier
5.1.1 Haselmeier Markets Five Injection Systems
5.1.1.1 Axis Pen Systems
5.1.1.2 i-Pen: Haselmeier's Insulin Pen Injector
5.1.2 Company Growth in Germany and India
5.1.3 Haselmeier: Opportunities for Expansion 2013-2023
5.2 Owen Mumford
5.2.1 Autoinjector and Pen Injector Overview
5.2.1.1 Autoject
5.2.1.2 Autopen
5.2.1.3 SimpleJect: Designed for RA Patients
5.2.2 Recent Financial Performance
5.2.3 Innovative Products to Drive Growth
5.2.4 Expanding in Established and New Markets
5.2.5 Owen Mumford: SWOT Analysis 2013-2023
5.2.6 Owen Mumford: Company Revenue Forecast 2013-2023
5.3 SHL Group
5.3.1 SHL Manufactures a Broad Range of Injection Devices
5.3.1.1 Molly Autoinjector
5.3.1.2 DAI Autoinjectors
5.3.2 SHL Group Continues to Grow in Taiwan
5.3.3 SHL Group: Pen Injector and Autoinjector Market Outlook 2013-2023
5.4 Ypsomed
5.4.1 Product Portfolio
5.4.1.1 YpsoPen
5.4.1.2 ServoPen
5.4.1.3 UnoPen
5.4.1.4 LyoTwist Injectors for Lyophilised Drugs
5.4.1.5 Ypsomed Markets Two Autoinjectors
5.4.2 Ypsomed: Financial Performance 2009-2012
5.4.2.1 Continued Delivery Devices Revenue Decline for FY 2013
5.4.3 A Focus on Diabetes
5.4.4 What Are Ypsomed's Strengths in the Pre-Fill Injection Device Market 2013?
5.4.5 Ypsomed Delivery Devices Revenue Forecast 2013-2023
5.4.6 Ypsomed: Company Insight
5.5 Pen Injector and Autoinjector Manufacturers: Competitor Analysis 2013-2023
5.5.1 A Highly Competitive Market 2013-2023
5.5.2 How Are Companies Differentiating Their Autoinjectors?
5.5.3 Rising Demand in At-Home Care
5.5.3.1 Specific Demands in RA and MS
5.5.4 Contract Manufacturing for Autoinjectors
6. LEADING PRE-FILLED SYRINGE CONTRACT MANUFACTURERS 2013-2023
6.1 Catalent is the World's Largest CMO
6.1.1 Pre-Filled Syringe Contract Manufacturing Capabilities
6.1.2 Catalent Offers an Autoinjector
6.1.3 Catalent Pharma Solutions: Financial Performance 2011-2012
6.1.4 Expanding Filling Capacity for Clinical Trial Materials
6.1.5 Catalent: SWOT Analysis 2013-2023
6.1.6 Catalent Pre-Filled Syringe and Cartridge Filling Revenue Forecast 2013-2023
6.2 Hospira One2One
6.2.1 Hospira and the Pre-Filled Injection Device Industry
6.2.1.1 iSecure Syringe: Hospira's Pre-Filled Injection System
6.2.2 Facility Expansion in Emerging Markets
6.2.3 Hospira: Market Outlook 2013-2023
6.2.4 Hospira One2One: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.3 Vetter Pharma
6.3.1 Vetter Is an Injectable Manufacturing Specialist
6.3.2 Vetter Grows in the US and Germany
6.3.3 New Services and Collaborations
6.3.4 Vetter: SWOT Analysis 2013-2023
6.3.5 Outlook for Vetter: Pre-Filled Injection Device Revenue Forecast 2013-2023
6.4 The Competitive Outlook for Leading CMOs in the Market 2013-2023
6.4.1 Biologics, Lyophilisation and Dual-Chamber Syringes
6.4.2 An Increasingly Competitive Market?
6.5 Other Pre-Filled Syringe Contract Manufacturers 2013
6.5.1 ROVI Has the Capacity to be a Market Leader
6.5.1.1 ROVI CM's Pre-Filled Syringe Capabilities
6.5.2 AMRI Entered the Market Through its Acquisition of HCM
6.5.2.1 AMRI's Recent Financial Performance
6.5.3 Boehringer Ingelheim
7. CONCLUSIONS FROM OUR STUDY
7.1 Outlook for the Pre-Filled Injection System Market 2013-2023
7.2 Outlook for Leading Pre-Filled Injection System Manufacturers 2013-2023
7.2.1 How Will the Leading Companies' Revenues Grow to 2023?
7.3 Company Insight Analysis: Common and Different Growth Strategies 2013-2023
7.3.1 How Have Customer Demands Changed in Recent Years?
7.3.1.1 How Will These Demands Change in the Future?
7.3.2 How Important Will Emerging Markets Be in this Decade?
7.4 Concluding Remarks
LIST OF TABLES
Table 1.1 Currency Exchange Rates, 2012
Table 2.1 Pre-Filled Injection Device Market, 2011
Table 2.2 Pre-Filled Injection Device Market by Region, 2011
Table 2.3 Pre-Filled Injection Device Market Forecast, 2011, 2017 and 2023
Table 2.4 Pre-Filled Injection Device Market: STEP Analysis, 2013-2023
Table 2.5 Selected Acquisitions in the Pre-Filled Injection Device Market, 2010-2012
Table 3.1 BD: Key Facts, 2013
Table 3.2 BD: Revenue by Division, 2010-2012
Table 3.3 BD Medical: Revenue by Division, 2011-2012
Table 3.4 BD Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.5 BD Pharmaceutical Systems: Revenue Forecast, 2012-2023
Table 3.6 Gerresheimer: Employees by Region, 2012
Table 3.7 Gerresheimer: Key Facts, 2013
Table 3.8 Gerresheimer: Revenue by Division, 2010-2012
Table 3.9 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.10 Gerresheimer Pen Injectors: Revenue Forecast, 2012-2023
Table 3.11 Schott: Key Facts, 2013
Table 3.12 Schott: Revenue, 2008-2011
Table 3.13 Schott Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.14 Nipro: Key Facts, 2013
Table 3.15 Nipro Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.16 Nuova Ompi: Key Facts, 2013
Table 3.17 Nuova Ompi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.18 Pre-Filled Syringes: Leading Product Comparisons, 2013
Table 3.19 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2013
Table 3.20 Unilife: Revenue, 2008-2012
Table 3.21 Revolutions Medical: RevVac Distribution Agreements, 2011-2012
Table 4.1 Aptar Stelmi: Key Facts, 2013
Table 4.2 Aptar Stelmi: Revenue, 1999-2012
Table 4.3 Aptar Stelmi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.4 Aptar Stelmi: Revenue Forecast, 2012-2023
Table 4.5 Datwyler: Key Facts, 2013
Table 4.6 Datwyler: Pharma Packaging Revenue, 2007-2012
Table 4.7 Datwyler Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.8 Datwyler Pharma Packaging: Revenue Forecast, 2012-2023
Table 4.9 West: Selected Pharmaceutical Industry Partners, 2013
Table 4.10 West: Key Facts, 2013
Table 4.11 West: Revenue by Division, 2009-2011
Table 4.12 West Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.13 West: Pre-Filled Syringe and Device Revenue, 2009-2011
Table 4.14 West Pre-Filled Injection Devices: Revenue Forecast, 2012-2023
Table 5.1 Haselmeier: Key Facts, 2013
Table 5.2 Selected Partners for the i-Pen, 2013
Table 5.3 Haselmeier Injection Devices: SWOT Analysis, 2013-2023
Table 5.4 Owen Mumford: Key Facts, 2013
Table 5.5 Selected Partners for the i-Pen, 2013
Table 5.6 Owen Mumford: Revenue by Region, 2010-2011
Table 5.7 Owen Mumford Injection Devices: SWOT Analysis, 2013-2023
Table 5.8 Chinese Insulin Market by Company, 2012
Table 5.9 Owen Mumford: Revenue Forecast, 2012-2023
Table 5.10 SHL Group: Key Facts, 2013
Table 5.11 SHL Group: Pen Injectors and Autoinjectors, 2013
Table 5.12 SHL Group Injection Devices: SWOT Analysis, 2013-2023
Table 5.13 Ypsomed: Key Facts, 2013
Table 5.14 Ypsomed: Pen Injectors and Autoinjectors, 2013
Table 5.15 Selected Pharmaceutical Partners for Ypsomed's Pen Injectors, 2013
Table 5.16 LyoTwist Injectors Available, 2013
Table 5.17 Ypsomed: Revenue by Division, 2009-2012
Table 5.18 Ypsomed: Revenue by Division, H1 2012-2013
Table 5.19 Ypsomed Injection Devices: SWOT Analysis, 2013-2023
Table 5.20 Ypsomed Delivery Devices: Revenue Forecast, 2012-2023
Table 5.21 Pen Injectors: Product Comparisons, 2013
Table 5.22 Autoinjectors: Product Comparisons, 2013
Table 5.23 Selected Other Pen Injector and Autoinjector Manufacturers, 2013
Table 6.1 Catalent: Employees by Region, 2013
Table 6.2 Catalent: Key Facts, 2013
Table 6.3 Catalent: Revenue by Division, 2011-2012
Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.5 Catalent Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.6 Hospira One2One: Key Facts, 2013
Table 6.7 Hospira Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.8 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.9 Vetter Pharma: Key Facts, 2013
Table 6.10 Vetter Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.11 Vetter Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.12 Leading Pre-Filled Syringe CMOs: Company Comparison, 2013
Table 7.1 Leading Pre-Filled Injection Device Manufacturers: Revenue Growth, 2012-2023
Table 7.2 Company Insight: Changing Customer Demands
Table 7.3 Company Insight: Pharmaceutical Industry Trends Influencing the Pre-Filled Injection Device Industry
Table 7.4 Company Insight: Future Expectations for Customer Demand, 2013-2023
Table 7.5 Company Insight: Emerging Market Expectations, 2013-2023
Table 1.1 Currency Exchange Rates, 2012
Table 2.1 Pre-Filled Injection Device Market, 2011
Table 2.2 Pre-Filled Injection Device Market by Region, 2011
Table 2.3 Pre-Filled Injection Device Market Forecast, 2011, 2017 and 2023
Table 2.4 Pre-Filled Injection Device Market: STEP Analysis, 2013-2023
Table 2.5 Selected Acquisitions in the Pre-Filled Injection Device Market, 2010-2012
Table 3.1 BD: Key Facts, 2013
Table 3.2 BD: Revenue by Division, 2010-2012
Table 3.3 BD Medical: Revenue by Division, 2011-2012
Table 3.4 BD Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.5 BD Pharmaceutical Systems: Revenue Forecast, 2012-2023
Table 3.6 Gerresheimer: Employees by Region, 2012
Table 3.7 Gerresheimer: Key Facts, 2013
Table 3.8 Gerresheimer: Revenue by Division, 2010-2012
Table 3.9 Gerresheimer Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 3.10 Gerresheimer Pen Injectors: Revenue Forecast, 2012-2023
Table 3.11 Schott: Key Facts, 2013
Table 3.12 Schott: Revenue, 2008-2011
Table 3.13 Schott Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.14 Nipro: Key Facts, 2013
Table 3.15 Nipro Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.16 Nuova Ompi: Key Facts, 2013
Table 3.17 Nuova Ompi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 3.18 Pre-Filled Syringes: Leading Product Comparisons, 2013
Table 3.19 Leading Pre-Filled Syringe Manufacturers: Comparative Product Ranges, 2013
Table 3.20 Unilife: Revenue, 2008-2012
Table 3.21 Revolutions Medical: RevVac Distribution Agreements, 2011-2012
Table 4.1 Aptar Stelmi: Key Facts, 2013
Table 4.2 Aptar Stelmi: Revenue, 1999-2012
Table 4.3 Aptar Stelmi Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.4 Aptar Stelmi: Revenue Forecast, 2012-2023
Table 4.5 Datwyler: Key Facts, 2013
Table 4.6 Datwyler: Pharma Packaging Revenue, 2007-2012
Table 4.7 Datwyler Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.8 Datwyler Pharma Packaging: Revenue Forecast, 2012-2023
Table 4.9 West: Selected Pharmaceutical Industry Partners, 2013
Table 4.10 West: Key Facts, 2013
Table 4.11 West: Revenue by Division, 2009-2011
Table 4.12 West Pre-Filled Syringes: SWOT Analysis, 2013-2023
Table 4.13 West: Pre-Filled Syringe and Device Revenue, 2009-2011
Table 4.14 West Pre-Filled Injection Devices: Revenue Forecast, 2012-2023
Table 5.1 Haselmeier: Key Facts, 2013
Table 5.2 Selected Partners for the i-Pen, 2013
Table 5.3 Haselmeier Injection Devices: SWOT Analysis, 2013-2023
Table 5.4 Owen Mumford: Key Facts, 2013
Table 5.5 Selected Partners for the i-Pen, 2013
Table 5.6 Owen Mumford: Revenue by Region, 2010-2011
Table 5.7 Owen Mumford Injection Devices: SWOT Analysis, 2013-2023
Table 5.8 Chinese Insulin Market by Company, 2012
Table 5.9 Owen Mumford: Revenue Forecast, 2012-2023
Table 5.10 SHL Group: Key Facts, 2013
Table 5.11 SHL Group: Pen Injectors and Autoinjectors, 2013
Table 5.12 SHL Group Injection Devices: SWOT Analysis, 2013-2023
Table 5.13 Ypsomed: Key Facts, 2013
Table 5.14 Ypsomed: Pen Injectors and Autoinjectors, 2013
Table 5.15 Selected Pharmaceutical Partners for Ypsomed's Pen Injectors, 2013
Table 5.16 LyoTwist Injectors Available, 2013
Table 5.17 Ypsomed: Revenue by Division, 2009-2012
Table 5.18 Ypsomed: Revenue by Division, H1 2012-2013
Table 5.19 Ypsomed Injection Devices: SWOT Analysis, 2013-2023
Table 5.20 Ypsomed Delivery Devices: Revenue Forecast, 2012-2023
Table 5.21 Pen Injectors: Product Comparisons, 2013
Table 5.22 Autoinjectors: Product Comparisons, 2013
Table 5.23 Selected Other Pen Injector and Autoinjector Manufacturers, 2013
Table 6.1 Catalent: Employees by Region, 2013
Table 6.2 Catalent: Key Facts, 2013
Table 6.3 Catalent: Revenue by Division, 2011-2012
Table 6.4 Catalent Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.5 Catalent Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.6 Hospira One2One: Key Facts, 2013
Table 6.7 Hospira Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.8 Hospira One2One Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.9 Vetter Pharma: Key Facts, 2013
Table 6.10 Vetter Pre-Filled Injection Devices: SWOT Analysis, 2013-2023
Table 6.11 Vetter Pre-Filled Injection Device Filling: Revenue Forecast, 2012-2023
Table 6.12 Leading Pre-Filled Syringe CMOs: Company Comparison, 2013
Table 7.1 Leading Pre-Filled Injection Device Manufacturers: Revenue Growth, 2012-2023
Table 7.2 Company Insight: Changing Customer Demands
Table 7.3 Company Insight: Pharmaceutical Industry Trends Influencing the Pre-Filled Injection Device Industry
Table 7.4 Company Insight: Future Expectations for Customer Demand, 2013-2023
Table 7.5 Company Insight: Emerging Market Expectations, 2013-2023
Datwyler: SWOT Analysis
Visiongain believes that Datwyler is one of the two largest global manufacturers of pre-filled syringe components. The company has been able to grow strongly in the past decade mostly through organic growth. Datwyler offers a range of pre-filled syringe components that appeal to a range of pharmaceutical clients (Table 4.7). For example, it offers standard rubber needle shields and tip caps, as well as high value components, such as those using its Omniflex coating for silicone free syringes.
Datwyler has the lead over its rivals in emerging market expansion and reports that it will be the first global component manufacturer to have its own manufacturing facility in India. The company is also focused on expansion in China. These two markets will be important for the company in the second half of the forecast period of this report, visiongain believes, given the rapidly rising incidence of diabetes there. We note that Datwyler identified insulin manufacturers as a target market for expansion in the future. As well as allowing Datwyler to enter these emerging markets in the medium term, establishing manufacturing facilities in India and China should help the company to cut the costs of manufacturing its pre-filled syringe components in the near term. In its recent annual reports, the company notes that price rises, driven by commodity prices have impacted company revenue and profitability. By producing the components cheaper in emerging markets, Datwyler should be able to offer its products to its clients at a competitive price.As well as expansion into emerging markets, Datwyler is looking for organic growth in the US and Europe, in response to growing demands for its high-value components. These high-value components include its Omniflex-coated products, as well as components for lyophilised drugcontainers. The increased development of biopharmaceuticals in the US and EU will drive demand for these products, as will continued development of cytotoxic drugs. Like other companies in the pre-filled injection device industry, Datwyler will benefit in the coming decade from partnering with leading pharmaceutical companies to co-develop its products. This will lead to long-term supply agreements, as well as the development of products suitable for novel drug programmes.
What Will Drive Growth for Datwyler Pharma Packaging to 2023?
Although Datwyler’s Pharma Packaging division no longer exists, visiongain has forecast the revenue for the products from this division for the period 2011-2023. Datwyler reports that the division, which manufactured rubber, plastic and aluminium products for pre-filled syringes, pen injectors, disposable syringe and IV systems, grew faster than the market as a whole in 2010 and 2011. In the first half of 2012, the company reported continued strong revenue growth for the division. From 2013 onwards, increased demand for its Omniflex coated products, both in developed markets and Asia will drive revenue growth for Datwyler. In the US and Europe demand for the Datwyler FirstLine services will drive revenue growth -Datwyler recently expanded its capacity for these services to meet the expected increased demand. Demand in these markets will also be driven by the development of sensitive biological drugs. Biosimilars in emerging markets will also drive demand for these components. Between 2011 and 2023, Datwyler’s Parma Packaging revenue will grow with a CAGR of 6.2%, reaching $581m in the latter year (Table 4.8 and Figure 4.4). Growth will be fastest in the first half of the forecast period, when revenue will grow with a CAGR of 7.3%.
